NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.

Abstract

Tumor heterogeneity presents a substantial barrier to increasing clinical responses mediated by targeted therapies. Broadening the immune response elicited by treatments that target a single antigen is necessary for the elimination of tumor variants that fail to express the targeted antigen. In this study, it is shown that adoptive transfer of T cells bearing a chimeric antigen receptor (CAR) inhibited the growth of target-expressing and -deficient tumor cells within ovarian and lymphoma tumors. Mice bearing the ID8 ovarian or RMA lymphoma tumors were treated with T cells transduced with a NKG2D-based CAR (chNKG2D). NKG2D CAR T-cell therapy protected mice from heterogeneous RMA tumors. Moreover, adoptive transfer of chNKG2D T cells mediated tumor protection against highly heterogeneous ovarian tumors in which 50, 20 or only 7% of tumor cells expressed significant amounts of NKG2D ligands. CAR T cells did not mediate an in vivo response against tumor cells that did not express sufficient amounts of NKG2D ligands, and the number of ligand-expressing tumor cells correlated with therapeutic efficacy. In addition, tumor-free surviving mice were protected against a tumor re-challenge with NKG2D ligand-negative ovarian tumor cells. These data indicate that NKG2D CAR T-cell treatment can be an effective therapy against heterogeneous tumors and induce tumor-specific immunity against ligand-deficient tumor cells.

• Authors: Paul Spear, Amorette Barber, Agnieszka Rynda-Apple, Charles L Sentman
• Journal: Immunology and cell biology (Immunol Cell Biol) Vol. 91 Issue 6 Pg. 435-40 (Jul 2013) ISSN: 1440-1711 [Electronic] United States
• PMID: 23628805 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• NK Cell Lectin-Like Receptor Subfamily K
• Recombinant Fusion Proteins
• Interferon-gamma

Topics

• Animals
• Cell Growth Processes (immunology)
• Cell Line, Tumor
• Cytotoxicity, Immunologic
• Female
• Humans
• Immunotherapy, Adoptive (methods)
• Interferon-gamma (metabolism)
• Lymphoma (immunology, therapy)
• Mice
• Mice, Inbred C57BL
• NK Cell Lectin-Like Receptor Subfamily K (genetics, metabolism)
• Natural Killer T-Cells (immunology, transplantation)
• Ovarian Neoplasms (immunology, therapy)
• Recombinant Fusion Proteins (genetics, metabolism)